China's WuXi AppTec, Wuxi Biologics plunge to multi-year lows on fears over US biotech bill
Reuters
Published Feb 02, 2024 04:57AM ET
Updated Feb 02, 2024 09:15AM ET
By Summer Zhen
HONG KONG (Reuters) - Shares of WuXi AppTec Co Ltd and WuXi Biologics (HK:2269) (Cayman) tumbled on Friday as investor fears grew over a U.S. draft bill targeting Chinese biotech giants.
Wuxi AppTec plunged 21.2% on Friday, hitting its lowest since August 2019, and Wuxi Biologics lost 20.7%, dropping to a five-year low.
Wuxi AppTec's Shanghai-listed stocks also fell by the daily price limit of 10%.
A U.S. congressional committee focused on China introduced a bill last week that would restrict federally funded medical providers from contacting WuXi AppTec and other Chinese biotech companies, citing Wuxi AppTec's military ties as part of the reason.
Wuxi AppTec, which provides drug R&D and manufacturing services, has denied any ties to China's military and said its business does not pose national security risks to any country.
Investor concerns mounted this week, however, and many dumped Chinese biotech shares on Friday following an analyst call organised by BofA Global Research, according to market participants and a meeting note sent to clients that was reviewed by Reuters.
Andrew Bressler, a U.S. medical policy analyst at BofA told investors he expects the proposed Biosecure Act Bill to move forward soon.
"Many investors are parking money and hoping to hear some turnaround scenarios ... but they might get a bit disappointed," said the BofA meeting note.
BofA declined to comment on the Friday meeting.
Spreading geopolitical risks have resulted in the underperformance of biotech companies and added to local market pessimism, UBS analysts also said in a note on Friday.
China's blue-chip CSI 300 Index dropped 1.2%, and the Hang Seng Hong Kong-listed Biotech Index slumped 5%.
WuXi AppTec said on Friday it plans to buy back 1 billion yuan ($140 million) of its Shanghai-listed shares to safeguard company value and shareholders' interests, but the announcement failed to restore investor confidence.
WuXi AppTec's Hong Kong shares have sunk 45% so far in 2024, and its Shanghai shares are down 31%.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.